

Striking antibody evasion manifested by the Omicron v

Nature

602, 676-681

DOI: [10.1038/s41586-021-04388-0](https://doi.org/10.1038/s41586-021-04388-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Lab-grown structures mimic human embryo's earliest stage yet. <i>Nature</i> , 2021, 591, 510-511.	13.7	3
3	Pathophysiology of COVID-19-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2021, 17, 751-764.	4.1	280
4	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
5	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
6	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
7	SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. <i>BioDrugs</i> , 2022, 36, 41-53.	2.2	26
8	Omicron, the great escape artist. <i>Nature Reviews Immunology</i> , 2022, 22, 75-75.	10.6	87
10	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 602, 682-688.	13.7	395
12	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. <i>Nature</i> , 2022, 603, 693-699.	13.7	460
13	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. <i>Cell Reports Medicine</i> , 2022, 3, 100527.	3.3	47
14	Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective. <i>Molecules</i> , 2022, 27, 658.	1.7	24
15	Searching for escape-resistant anti-SARS-CoV-2 neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
16	SARS-CoV-2 Virology. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 251-265.	1.9	7
18	Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. <i>Emerging Microbes and Infections</i> , 2022, 11, 477-481.	3.0	104
20	T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. <i>Cellular and Molecular Immunology</i> , 2022, 19, 447-448.	4.8	68
21	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. <i>Nature Medicine</i> , 2022, 28, 472-476.	15.2	333
25	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	13.5	165
26	The puzzling mutational landscape of the SARS-CoV-2 variant Omicron. <i>Journal of Medical Virology</i> , 2022, 94, 2019-2025.	2.5	63

#	ARTICLE	IF	CITATIONS
30	Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 639.	3.8	539
31	The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion. <i>Viruses</i> , 2022, 14, 294.	1.5	85
32	Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. <i>Emerging Microbes and Infections</i> , 2022, 11, 567-572.	3.0	39
39	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. <i>Cell</i> , 2022, 185, 847-859.e11.	13.5	590
40	Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. <i>Cell</i> , 2022, 185, 860-871.e13.	13.5	310
42	Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas. <i>Emerging Microbes and Infections</i> , 2022, 11, 306-309.	3.0	9
43	SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex. <i>Science</i> , 2022, 375, 760-764.	6.0	488
44	Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. <i>Nature Medicine</i> , 0, , .	15.2	14
46	The Impact of Accumulated Mutations in SARS-CoV-2 Variants on the qPCR Detection Efficiency. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 823306.	1.8	8
51	Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. <i>Nature</i> , 2022, 603, 700-705.	13.7	447
52	Boosting immunity after CoronaVac. <i>Lancet, The</i> , 2022, 399, 496-497.	6.3	4
53	A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. <i>International Immunopharmacology</i> , 2022, 105, 108565.	1.7	44
54	ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 43.	7.1	14
57	SARS-CoV-2 Omicron variant: A next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine. <i>MedComm</i> , 2022, 3, e119.	3.1	45
59	Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. <i>Vaccines</i> , 2022, 10, 270.	2.1	8
60	Cryo-EM structure of the SARS-CoV-2 Omicron spike. <i>Cell Reports</i> , 2022, 38, 110428.	2.9	82
61	Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. <i>Science</i> , 2022, 375, 1048-1053.	6.0	216
66	SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. <i>Science Immunology</i> , 2022, 7, eabn8590.	5.6	88

#	ARTICLE	IF	CITATIONS
67	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
68	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 44.	7.1	31
70	Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 642-652.	1.9	161
72	The Coronavirus pandemic 2022: Viruses, variants & vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 1-9.	3.2	31
73	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 0, , .	13.7	56
76	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
77	Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
78	Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study. <i>Infection and Chemotherapy</i> , 2022, 54, 91.	1.0	9
80	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
81	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1987.	1.8	48
82	Boosting immunity to Omicron. <i>Nature Medicine</i> , 2022, 28, 445-446.	15.2	29
84	Molecular basis of receptor binding and antibody neutralization of Omicron. <i>Nature</i> , 2022, 604, 546-552.	13.7	135
87	How to organise travel restrictions in the new future: lessons from the COVID-19 response in Hong Kong and Singapore. <i>BMJ Global Health</i> , 2022, 7, e006975.	2.0	4
88	Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. <i>Vaccines</i> , 2022, 10, 367.	2.1	38
89	Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 55.	7.1	9
90	Literature Review of Omicron: A Grim Reality Amidst COVID-19. <i>Microorganisms</i> , 2022, 10, 451.	1.6	32
95	Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2078.	1.8	5
98	Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. <i>Cell Research</i> , 2022, 32, 401-403.	5.7	37

#	ARTICLE	IF	CITATIONS
100	Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City. <i>Viruses</i> , 2022, 14, 545.	1.5	23
101	Identification of cell type specific ACE2 modifiers by CRISPR screening. <i>PLoS Pathogens</i> , 2022, 18, e1010377.	2.1	9
102	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0273221.	1.2	35
103	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 103960.	1.9	16
104	Antibody evasion properties of SARS-CoV-2 Omicron sublineages. <i>Nature</i> , 2022, 604, 553-556.	13.7	649
105	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	13.5	71
106	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	6.0	177
107	â€œs Omicron mildâ€? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. <i>Journal of Medical Virology</i> , 2022, 94, 3521-3539.	2.5	20
109	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
110	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
112	SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. <i>EBioMedicine</i> , 2022, 77, 103940.	2.7	3
113	The (apparent) antibody paradox in COVID-19. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 335-345.	1.3	9
114	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
115	Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak. <i>Clinical Infectious Diseases</i> , 2022, 75, e44-e49.	2.9	66
116	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
118	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2122954119.	3.3	57
119	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. <i>Cell</i> , 2022, 185, 1389-1401.e18.	13.5	82
121	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25

#	ARTICLE	IF	CITATIONS
122	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. <i>Frontiers in Immunology</i> , 2022, 13, 835104.	2.2	28
123	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
126	Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?. <i>Journal of Virology</i> , 2022, 96, jvi0207721.	1.5	143
127	Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. <i>Cell Research</i> , 2022, 32, 491-494.	5.7	17
128	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
129	Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern. <i>IScience</i> , 2022, 25, 103968.	1.9	14
130	Biparatopic antibodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. <i>EMBO Reports</i> , 2022, 23, e54199.	2.0	30
131	Immunity Against the Omicron Variant From Vaccination, Recovery, or Both. <i>Clinical Infectious Diseases</i> , 2022, 75, e672-e674.	2.9	2
132	Omicron Variant of SARS-CoV-2 Virus: In Silico Evaluation of the Possible Impact on People Affected by Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2022, 13, 847993.	1.5	8
133	Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective. <i>ChemBioChem</i> , 2022, 23, e202200059.	1.3	35
136	35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. <i>Cell Host and Microbe</i> , 2022, 30, 887-895.e4.	5.1	20
137	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
138	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. <i>MBio</i> , 2022, 13, e0379821.	1.8	28
139	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	84
140	Global trends in COVID-19. , 2022, 1, 31-39.		8
142	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2083-2088.	2.6	64
144	Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?. <i>Molecules</i> , 2022, 27, 2221.	1.7	12
145	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2022, 17, e0265453.	1.1	8

#	ARTICLE	IF	CITATIONS
146	Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions. <i>GeroScience</i> , 2022, 44, 619-637.	2.1	39
148	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
149	The Transmission, Infection Prevention, and Control during the COVID-19 Pandemic in China: A Retrospective Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3074.	1.2	4
151	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 914-925.	3.0	8
152	The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. <i>Journal of Personalized Medicine</i> , 2022, 12, 439.	1.1	6
153	SARS-CoV-2 Omicron variant: Immune escape and vaccine development. <i>MedComm</i> , 2022, 3, e126.	3.1	74
154	Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. <i>Cell</i> , 2022, 185, 1539-1548.e5.	13.5	126
155	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
156	Unwinding Link between Coronavirus and Diabetes Patient. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1091-1110.	0.6	0
157	Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report. <i>Vaccines</i> , 2022, 10, 450.	2.1	1
158	Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). <i>Biology</i> , 2022, 11, 400.	1.3	10
160	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
162	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
163	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. <i>New England Journal of Medicine</i> , 2022, 386, 1579-1580.	13.9	296
164	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
166	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1873-1883.	2.6	37
168	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	5.8	75
169	Molnupiravir and Its Antiviral Activity Against COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 855496.	2.2	81

#	ARTICLE	IF	CITATIONS
172	Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. <i>MedComm</i> , 2022, 3, e130.	3.1	18
173	There is nothing exempt from the peril of mutation – The Omicron spike. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112756.	2.5	11
174	Omicron™s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. <i>IScience</i> , 2022, 25, 104076.	1.9	25
175	Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron™s outbreak. <i>PLoS ONE</i> , 2022, 17, e0266270.	1.1	11
176	Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. <i>Med</i> , 2022, 3, 249-261.e4.	2.2	56
177	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. <i>EBioMedicine</i> , 2022, 79, 103986.	2.7	23
179	A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues. , 2022, 19, 647-649.		4
181	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	2.9	47
184	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	5.8	31
185	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
186	Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases. <i>Frontiers in Genetics</i> , 2022, 13, 892682.	1.1	7
187	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
189	COVID-19 and tuberculosis: the double whammy of respiratory pathogens. <i>European Respiratory Review</i> , 2022, 31, 210264.	3.0	40
190	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729.	2.9	102
194	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939.	2.0	41
195	Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals. <i>JAMA Network Open</i> , 2022, 5, e2210871.	2.8	42
196	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. <i>EBioMedicine</i> , 2022, 78, 103944.	2.7	119
197	Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 3840-3849.	2.1	79

#	ARTICLE	IF	CITATIONS
198	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
199	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. <i>Science Immunology</i> , 2022, 7, eabp9312.	5.6	35
200	Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science. <i>Physiological Reviews</i> , 2022, 102, 1569-1577.	13.1	9
201	<i>Bacillus Calmette-Guérin</i> induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. <i>JCI Insight</i> , 2022, 7, .	2.3	29
203	Rapid Genotyping of Sars-Cov-2 Variants with a Duplex-Targeting Lateral Flow Strip by Crispr-Cas 12a/13a in Pam Independent Manner. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
204	Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, e1391.	1.7	21
205	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
206	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
207	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
209	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 139.	7.1	14
210	Characterization and functional interrogation of the SARS-CoV-2 RNA interactome. <i>Cell Reports</i> , 2022, 39, 110744.	2.9	30
211	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	7.1	315
212	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101.	2.2	74
213	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
214	An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. <i>Nature Microbiology</i> , 2022, 7, 716-725.	5.9	62
215	Multifactorial Effects of COVID-19: A Review of Published Autopsy Reports. <i>Covid</i> , 2022, 2, 553-568.	0.7	1
216	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
218	The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. <i>Journal of Biomedical Science</i> , 2022, 29, 27.	2.6	9

#	ARTICLE	IF	CITATIONS
219	Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. <i>Blood</i> , 2022, 140, 152-156.	0.6	17
220	Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. <i>Science Translational Medicine</i> , 2022, 14, eabn6868.	5.8	62
221	Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. <i>Science Immunology</i> , 2022, 7, eabq3511.	5.6	82
222	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. <i>Cell Reports</i> , 2022, 39, 110862.	2.9	9
223	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	3.3	27
224	Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. <i>Microbiology Spectrum</i> , 2022, 10, e0079122.	1.2	19
225	Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118312119.	3.3	86
226	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. <i>Cell</i> , 2022, 185, 2103-2115.e19.	13.5	273
227	Emerging SARS-CoV-2 variants: Why, how, and what's next?., 2022, 1, 100029.		26
228	T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3998-4004.	2.5	20
229	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
230	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
231	Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. <i>Cell Host and Microbe</i> , 2022, 30, 1077-1083.e4.	5.1	132
233	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	39
234	Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. <i>Science Immunology</i> , 2022, 7, eabo3425.	5.6	28
235	Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters. <i>EBioMedicine</i> , 2022, 80, 104035.	2.7	4
236	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. <i>Viruses</i> , 2022, 14, 1029.	1.5	17
237	Infectivity versus fatality of SARS-CoV-2 mutations and influenza. <i>International Journal of Infectious Diseases</i> , 2022, 121, 195-202.	1.5	27

#	ARTICLE	IF	CITATIONS
238	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
239	Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Caseâ€“Control Study. <i>Vaccines</i> , 2022, 10, 779.	2.1	8
240	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
241	Long-term monitoring of SARS-CoV-2 RNA in sewage samples from specific public places and STPs to track COVID-19 spread and identify potential hotspots. <i>Science of the Total Environment</i> , 2022, 838, 155959.	3.9	11
242	The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. <i>Science Translational Medicine</i> , 2022, 14, eabm7621.	5.8	22
243	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. <i>Nature Microbiology</i> , 2022, 7, 909-917.	5.9	41
244	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	13.7	174
245	At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
246	Convalescent plasma donors show enhanced crossâ€“reactive neutralizing antibody response to antigenic variants of SARSâ€“CoVâ€“2 following immunization. <i>Transfusion</i> , 2022, 62, 1347-1354.	0.8	9
247	Diagnosis and management of covid-19 in pregnancy. <i>BMJ, The</i> , 2022, 377, e069739.	3.0	25
248	SARS-CoV-2 Deltaâ€“Omicron Recombinant Viruses, United States. <i>Emerging Infectious Diseases</i> , 2022, 28, 1442-1445.	2.0	35
249	Pyrazolone-type compounds: synthesis and <i>in silico</i> assessment of antiviral potential against key viral proteins of SARS-CoV-2. <i>RSC Advances</i> , 2022, 12, 16054-16070.	1.7	3
252	Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	4
253	Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. <i>Nature Communications</i> , 2022, 13, .	5.8	36
254	Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage. <i>Molecular Biology Reports</i> , 2022, 49, 10137-10140.	1.0	6
255	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
260	A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. <i>Journal of Medical Virology</i> , 2022, 94, 4287-4293.	2.5	13
263	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
264	Analysis of the Transmission of SARS-CoV-2 Delta VOC in Yantai, China, August 2021. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	0
265	VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages. <i>Journal of Personalized Medicine</i> , 2022, 12, 895.	1.1	2
266	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
267	Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104431.	1.9	3
268	Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron. <i>Virology Journal</i> , 2022, 19, .	1.4	5
269	Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals. <i>Vaccines</i> , 2022, 10, 813.	2.1	4
271	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
273	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. <i>Cell Reports</i> , 2022, 39, 110924.	2.9	20
274	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
275	Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins. <i>Cell Research</i> , 2022, 32, 609-620.	5.7	63
277	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6123.	1.8	9
278	Adaptation of new variants: A game changer in the evolution of SARS-CoV-2. , 0, .		0
280	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
281	The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1524-1536.	3.0	39
282	Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
283	Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
285	Research Progress of SARS-CoV-2 Omicron Variant. <i>Advances in Microbiology</i> , 2022, 11, 49-60.	0.0	0
286	Relative Effectiveness of COVID-19 Vaccination with 3 Compared to 2 Doses Against SARS-CoV-2 B.1.1.529 (Omicron) Among an Australian Population with Low Prior Rates of SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
287	Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. <i>New England Journal of Medicine</i> , 2022, 387, 86-88.	13.9	433
288	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
290	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	5.7	35
291	Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies. <i>Viruses</i> , 2022, 14, 1334.	1.5	45
292	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	1.5	12
293	Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	53
295	Modeling the early embryo. <i>Nature Methods</i> , 2022, 19, 644-648.	9.0	2
297	Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19. <i>ELife</i> , 0, 11, .	2.8	2
298	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
299	An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants. <i>Heliyon</i> , 2022, 8, e09660.	1.4	1
300	Omicron Spike Protein Has a Positive Electrostatic Surface That Promotes ACE2 Recognition and Antibody Escape. <i>Frontiers in Virology</i> , 0, 2, .	0.7	33
301	Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	2
303	Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2675-2681.	2.6	48
304	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
305	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. <i>Nature</i> , 2022, 608, 593-602.	13.7	889
306	Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S110-S120.	2.9	10
307	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
308	Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. <i>Journal of Virology</i> , 0, , .	1.5	3

#	ARTICLE	IF	CITATIONS
309	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
311	Therapeutics to tackle Omicron outbreak. <i>Immunotherapy</i> , 2022, 14, 833-838.	1.0	22
312	Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e336-e341.	2.9	18
313	Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. <i>Journal of Medical Virology</i> , 2022, 94, 4628-4643.	2.5	17
315	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	6.0	113
316	Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. <i>JAMA Internal Medicine</i> , 2022, 182, 859.	2.6	40
317	Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
318	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. <i>Nature Microbiology</i> , 2022, 7, 1252-1258.	5.9	20
319	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. <i>MBio</i> , 2022, 13, .	1.8	9
320	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
321	mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. <i>Cell Reports Medicine</i> , 2022, 3, 100653.	3.3	10
322	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010547.	2.1	12
323	Lessons learned from the COVID-19 control strategy of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics. <i>Emerging Microbes and Infections</i> , 2022, 11, 1711-1716.	3.0	7
324	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. <i>Science</i> , 2022, 377, .	6.0	241
325	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
326	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15
327	Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion. <i>Virology</i> , 2022, 573, 84-95.	1.1	1
328	Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immized Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
329	Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition. <i>Immune Network</i> , 2022, 22, .	1.6	1
330	Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	9
331	One-Year Follow-Up of COVID-19 Impact on Surgical Education: Clinical Training Restored but Surgical Trainee Emotional Well-Being Still at Risk. <i>Journal of the American College of Surgeons</i> , 2022, 235, 195-209.	0.2	3
332	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CoV recipients in a randomized phase 2 trial. <i>Nature Communications</i> , 2022, 13, .	5.8	26
333	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. <i>Nature Microbiology</i> , 2022, 7, 1063-1074.	5.9	63
334	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
336	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
337	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
338	Emerging SARS-CoV-2 Mutational Variants of Concern Should Not Vary in Susceptibility to Microbicidal Actives. <i>Life</i> , 2022, 12, 987.	1.1	0
339	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	2.1	13
341	A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. <i>Cell Research</i> , 2022, 32, 862-865.	5.7	8
342	A broad and potent neutralization epitope in SARS-related coronaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
343	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
344	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
346	An outlook on potential protein targets of COVID-19 as a druggable site. <i>Molecular Biology Reports</i> , 2022, 49, 10729-10748.	1.0	3
347	T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. , 2022, 10, e004953.		7
349	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
350	The COVID-19 Vaccination Still Matters: Omicron Variant Is a Final Wake-Up Call for the Rich to Help the Poor. <i>Vaccines</i> , 2022, 10, 1070.	2.1	10

#	ARTICLE	IF	CITATIONS
351	Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. <i>MSphere</i> , 2022, 7, .	1.3	3
352	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <i>Structure</i> , 2022, 30, 1233-1244.e7.	1.6	13
353	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55
354	Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e311-e326.	4.6	114
355	Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. <i>Biomolecules</i> , 2022, 12, 964.	1.8	0
356	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Clinical Infectious Diseases</i> , 2023, 76, e188-e199.	2.9	24
357	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	2.0	7
358	A booster dose of Delta-â€‰Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
359	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
361	Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (<sc>AZD7442</sc>) Administered Intravenously Versus Intramuscularly in Symptomatic <sc>SARSâ€‰CoV</sc>â€‰2 Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1207-1213.	2.3	8
362	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. <i>Nature Communications</i> , 2022, 13, .	5.8	43
363	Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. <i>BMJ</i> , The, 0, , e071502.	3.0	111
365	Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected With Delta or Omicron Variants. <i>Journal of Infectious Diseases</i> , 2022, 226, 1120-1122.	1.9	3
366	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. <i>Science</i> , 2022, 377, .	6.0	120
367	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	5.8	93
368	Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 280-287.	1.3	6
369	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature</i> , 2022, 608, 603-608.	13.7	541
370	Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104766.	1.9	13

#	ARTICLE	IF	CITATIONS
371	Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	11
372	A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries. Journal of Infection and Public Health, 2022, 15, 878-891.	1.9	24
373	Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814. Journal of Molecular Biology, 2022, 434, 167706.	2.0	10
374	Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Research, 2022, 205, 105372.	1.9	22
375	Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy. Pathogens, 2022, 11, 823.	1.2	14
376	Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. Nature Microbiology, 2022, 7, 1376-1389.	5.9	33
377	Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	96
378	Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. Viruses, 2022, 14, 1570.	1.5	10
380	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Science Immunology, 2022, 7, .	5.6	170
381	Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. Chem, 2022, 8, 2766-2783.	5.8	18
382	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Infection and Drug Resistance, 0, Volume 15, 4013-4027.	1.1	4
385	Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	6
386	Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. Cell Host and Microbe, 2022, 30, 1255-1268.e5.	5.1	45
387	Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine, 2022, 51, 101576.	3.2	14
388	The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants. Biomedicines, 2022, 10, 1839.	1.4	3
389	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines, 2022, 10, 1223.	2.1	12
391	Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022. Vaccines, 2022, 10, 1215.	2.1	11
392	CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	25

#	ARTICLE	IF	CITATIONS
394	Molecular adaptations during viral epidemics. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
396	Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3618-3626.	2.5	7
398	Function and Clinical Significance of Circular RNAs in Thyroid Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
399	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
400	Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	9
401	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1585-1593.	0.5	12
402	Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality. <i>Clinical Infectious Diseases</i> , 2023, 76, e126-e132.	2.9	48
403	An antibody from single human V _H -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. <i>Science Immunology</i> , 2022, 7, .	5.6	34
405	Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	145
406	Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers. <i>Journal of Medical Virology</i> , 2022, 94, 5867-5876.	2.5	17
407	Effectiveness of mRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1624-1628.	2.8	14
409	Preliminary Clinical Experience of Molnupiravir to Prevent Progression of COVID-19 in Kidney Transplant Recipients. <i>Transplantation</i> , 2022, 106, 2200-2204.	0.5	17
410	Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. <i>Nature Communications</i> , 2022, 13, .	5.8	66
411	Sublineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. <i>MedComm</i> , 2022, 3, .	3.1	15
412	Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey. <i>MBio</i> , 2022, 13, .	1.8	6
413	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6
414	Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. <i>Med</i> , 2022, 3, 705-721.e11.	2.2	10
417	Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. <i>Cell Host and Microbe</i> , 2022, 30, 1242-1254.e6.	5.1	27

#	ARTICLE	IF	CITATIONS
419	Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
420	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. <i>Science</i> , 2022, 25, 104914.	1.9	5
421	Effects of boosted mRNA and adenoviralâ€¢vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 5713-5722.	2.5	23
422	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. <i>JAMA Network Open</i> , 2022, 5, e2226335.	2.8	42
423	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. <i>MSphere</i> , 2022, 7, .	1.3	8
424	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
425	Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 1156-1170.	1.1	2
427	mRNA vaccines in the prevention and treatment of diseases. <i>MedComm</i> , 2022, 3, .	3.1	14
428	Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction. <i>Structural Chemistry</i> , 2022, 33, 1755-1769.	1.0	9
429	BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	29
430	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. <i>Microorganisms</i> , 2022, 10, 1676.	1.6	5
432	A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. <i>ELife</i> , 0, 11, .	2.8	10
434	T cell immunity to COVID-19 vaccines. <i>Science</i> , 2022, 377, 821-822.	6.0	117
435	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3
436	Phytochemical drug discovery for COVID-19 using high-resolution computational docking and machine learning assisted binder prediction. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6643-6663.	2.0	2
439	The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
440	Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing. , 2022, 1, .		3
441	Lineage BA.2 Dominated the Omicron SARS-CoV-2 Epidemic Wave in the Philippines. <i>Virus Evolution</i> , 0, , .	2.2	2

#	ARTICLE	IF	CITATIONS
442	A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. <i>Cell Reports</i> , 2022, 40, 111335.	2.9	2
443	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
444	Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. <i>Cell Host and Microbe</i> , 2022, 30, 1354-1362.e6.	5.1	28
445	SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> , 2022, 55, 1764-1778.	6.6	63
448	Same Old New Normal: The Ableist Fallacy of "Post-Pandemic" Work. <i>Social Inclusion</i> , 2022, 11, .	0.6	1
449	An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif. <i>Science Immunology</i> , 2022, 7, .	5.6	23
451	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
452	Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. <i>IScience</i> , 2022, 25, 104935.	1.9	8
453	Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon- γ release assay. <i>International Journal of Infectious Diseases</i> , 2022, 122, 841-849.	1.5	24
454	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 980-997.	3.6	28
455	Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. <i>Computers in Biology and Medicine</i> , 2022, 149, 105969.	3.9	7
456	Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 1977-1981.	2.0	8
457	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
458	Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery. <i>Molecular Therapy</i> , 2023, 31, 362-373.	3.7	0
459	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
460	Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using γ Map. <i>Journal of the American Chemical Society</i> , 2022, 144, 16604-16611.	6.6	8
461	Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control. <i>Vaccines</i> , 2022, 10, 1555.	2.1	4
462	A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld [®]) for COVID-19 Prophylaxis and Treatment. <i>Viruses</i> , 2022, 14, 1999.	1.5	34

#	ARTICLE	IF	CITATIONS
463	SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. Emerging Infectious Diseases, 2022, 28, .	2.0	7
464	Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants. Biochemical and Biophysical Research Communications, 2022, 627, 168-175.	1.0	6
465	Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Clinical Immunology, 2022, 244, 109103.	1.4	3
466	Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic. Science of the Total Environment, 2022, 853, 158458.	3.9	19
467	Evasion of Neutralizing Antibody Response by the SARS-CoC-2 BA.2.75 Variant. SSRN Electronic Journal, 0, , .	0.4	0
468	Analysis of co-occurring and mutually exclusive amino acid changes and detection of convergent and divergent evolution events in SARS-CoV-2. Computational and Structural Biotechnology Journal, 2022, 20, 4238-4250.	1.9	3
469	Targeting ACLY efficiently inhibits SARS-CoV-2 replication. International Journal of Biological Sciences, 2022, 18, 4714-4730.	2.6	4
470	Distinct core glycan and <i>O</i>-glycoform utilization of SARS-CoV-2 Omicron variant Spike protein RBD revealed by top-down mass spectrometry. Chemical Science, 2022, 13, 10944-10949.	3.7	13
471	Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway. International Journal of Biological Sciences, 2022, 18, 4744-4755.	2.6	12
472	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. SSRN Electronic Journal, 0, , .	0.4	0
473	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
474	Biophysical and structural characterizations of the effects of mutations on the structureâ€“activity relationships of SARS-CoV-2 spike protein. Methods in Enzymology, 2022, , 299-321.	0.4	2
475	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
476	The Fc-Effector Function of COVID-19 Convalescent Plasma Contributes to SARS-CoV-2 Treatment Efficacy in Mice. SSRN Electronic Journal, 0, , .	0.4	0
477	MgIn2S4@In2O3 hierarchical tubular heterostructures with expedited photocarrier separation for efficient visible-light-driven antimicrobial activity. Chemical Engineering Journal, 2023, 452, 139559.	6.6	10
479	Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater. Viruses, 2022, 14, 1876.	1.5	12
480	Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature, 2022, 611, 139-147.	13.7	69
481	A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	10

#	ARTICLE	IF	CITATIONS
483	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders. <i>Pharmaceuticals</i> , 2022, 15, 1084.	1.7	5
484	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
485	Reduced B cell antigenicity of Omicron lowers host serologic response. <i>Cell Reports</i> , 2022, 41, 111512.	2.9	5
486	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
487	Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
488	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
490	A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. <i>Cell Reports Medicine</i> , 2022, 3, 100774.	3.3	14
491	Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors. <i>Vaccines</i> , 2022, 10, 1617.	2.1	0
492	Covid-19 Vaccines - Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
493	Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. <i>Nature Communications</i> , 2022, 13, .	5.8	16
494	An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. <i>PLoS Pathogens</i> , 2022, 18, e1010828.	2.1	25
495	A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. <i>Nature Communications</i> , 2022, 13, .	5.8	37
496	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
498	Probing Mechanisms of Binding and Allostery in the SARS-CoV-2 Spike Omicron Variant Complexes with the Host Receptor: Revealing Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Communication with Allosteric Pockets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11542.	1.8	15
501	Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. <i>Cell Host and Microbe</i> , 2022, 30, 1518-1526.e4.	5.1	69
502	Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor. <i>Viruses</i> , 2022, 14, 2075.	1.5	9
503	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
506	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. <i>Science China Life Sciences</i> , 0, , .	2.3	2

#	ARTICLE	IF	CITATIONS
507	Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. <i>Cell Reports Medicine</i> , 2022, 3, 100764.	3.3	16
508	Molecular Insights into Striking Antibody Evasion of SARS-CoV-2 Omicron Variant. <i>Chinese Physics Letters</i> , 2022, 39, 108701.	1.3	3
509	Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
510	Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.	3.3	19
511	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
512	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. <i>Science Advances</i> , 2022, 8, .	4.7	22
513	Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
514	On the Origins of Omicron's Unique Spike Gene Insertion. <i>Vaccines</i> , 2022, 10, 1509.	2.1	10
515	Deep learning-based rapid generation of broadly reactive antibodies against SARS-CoV-2 and its Omicron variant. <i>Cell Research</i> , 2023, 33, 80-82.	5.7	5
516	SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
517	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. <i>Emerging Microbes and Infections</i> , 2022, 11, 2275-2287.	3.0	48
518	Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. <i>Science Immunology</i> , 2022, 7, .	5.6	49
519	SARS-CoV-2 reinfections during the Delta and Omicron waves. <i>JCI Insight</i> , 2022, 7, .	2.3	5
520	Genomic profile of SARS-CoV-2 Omicron variant and its correlation with disease severity in Rajasthan. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
521	Learning from our differences. <i>Nature Immunology</i> , 0, , .	7.0	0
522	COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. <i>Viruses</i> , 2022, 14, 2086.	1.5	12
523	Epistatic Variations in the Omicron Receptor Binding Domain Can Enhance Host Recognition: An <i>In Silico</i> Assessment and Prediction. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 8808-8815.	2.1	2
525	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 45-55.	4.6	55

#	ARTICLE	IF	CITATIONS
526	Immune Evasion of SARS-CoV-2 Omicron Subvariants. <i>Vaccines</i> , 2022, 10, 1545.	2.1	19
527	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. <i>Viruses</i> , 2022, 14, 1966.	1.5	6
528	Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. <i>Cell Host and Microbe</i> , 2022, 30, 1512-1517.e4.	5.1	73
529	Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. <i>European Biophysics Journal</i> , 2022, 51, 555-568.	1.2	4
530	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. <i>Cell</i> , 2022, 185, 3992-4007.e16.	13.5	167
531	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
532	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10091.	1.8	8
533	Evolving role of novel COVID-19 Medicine Delivery Units. <i>Integrated Healthcare Journal</i> , 2022, 4, e000135.	0.2	0
534	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
535	Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	17
536	Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
537	Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. <i>Cell Discovery</i> , 2022, 8, .	3.1	10
538	Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. <i>Vaccine</i> , 2022, 40, 6288-6294.	1.7	17
539	Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 511-524.	1.2	3
540	Continued Complexity of Mutations in Omicron Sublineages. <i>Biomedicines</i> , 2022, 10, 2593.	1.4	5
542	De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. <i>Science Advances</i> , 2022, 8, .	4.7	9
543	A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. <i>Journal of Clinical Practice</i> , 2022, 13, 43-55.	0.2	3
544	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1

#	ARTICLE	IF	CITATIONS
547	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	4.6	14
548	Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. , 2022, 19, 1392-1399.		5
549	Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons. <i>MBio</i> , 2022, 13, .	1.8	33
550	The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview. <i>Journal of Molecular Pathology</i> , 2022, 3, 201-218.	0.5	13
551	Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants. <i>Molecules</i> , 2022, 27, 7336.	1.7	1
552	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
554	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. <i>Science</i> , 2022, 378, 619-627.	6.0	117
555	METTL3 modulates chromatin and transcription dynamics during cell fate transition. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	6
557	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. <i>Nature Reviews Microbiology</i> , 2023, 21, 112-124.	13.6	128
558	Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2. <i>Cell Reports</i> , 2022, 41, 111650.	2.9	12
559	Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. <i>Cell Host and Microbe</i> , 2022, 30, 1732-1744.e7.	5.1	7
560	Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
562	Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes. <i>Immunity</i> , 2022, 55, 2419-2435.e10.	6.6	23
563	Post-acute health care burden after SARS-CoV-2 infection: a retrospective cohort study. <i>Cmaj</i> , 2022, 194, E1368-E1376.	0.9	17
564	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
566	Infection of the oral cavity with SARS-CoV-2 variants: Scope of salivary diagnostics. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
567	Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. <i>Virologica Sinica</i> , 2022, 37, 831-841.	1.2	2
568	An Engineered IgGâ€“VHH Bispecific Antibody against SARSâ€“CoVâ€“2 and Its Variants. <i>Small Methods</i> , 2022, 6, .	4.6	4

#	ARTICLE	IF	CITATIONS
569	Stability and expression of SARS-CoV-2 spike-protein mutations. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 1269-1280.	1.4	4
570	Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1666-1668.	4.6	50
571	ColdZyme® protects airway epithelia from infection with BA.4/5. <i>Respiratory Research</i> , 2022, 23, .	1.4	7
572	The health benefit of physical exercise on COVID-19 pandemic: Evidence from mainland China. <i>PLoS ONE</i> , 2022, 17, e0275425.	1.1	0
573	A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
574	Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. <i>Cell Host and Microbe</i> , 2022, 30, 1540-1555.e15.	5.1	96
575	Using machine learning models to predict the duration of the recovery of COVID-19 patients hospitalized in Fangcang shelter hospital during the Omicron BA. 2.2 pandemic. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
576	A bibliometric analysis of research related Chinese Medicine in the prevention and treatment of corona virus disease 2019. <i>Heliyon</i> , 2022, 8, e11120.	1.4	7
577	Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 465-476.	2.3	6
578	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
579	A case of multiple thrombosis and septic shock in a critically ill patient with Omicron infection. <i>Journal of Infection and Public Health</i> , 2022, 15, 1321-1325.	1.9	1
580	SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. <i>Immunoinformatics</i> , 2022, 8, 100020.	1.2	2
581	Natural selection pressure exerted on "Silent" mutations during the evolution of SARS-CoV-2: Evidence from codon usage and RNA structure. <i>Virus Research</i> , 2023, 323, 198966.	1.1	6
582	Rapid Emergence of the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Korea. <i>Annals of Laboratory Medicine</i> , 2023, 43, 211-213.	1.2	5
583	Exploring a COVID-19 Endemic Scenario: High-Resolution Agent-Based Modeling of Multiple Variants. <i>Advanced Theory and Simulations</i> , 0, , 2200481.	1.3	2
584	Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1. <i>Nature Communications</i> , 2022, 13, .	5.8	62
585	Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR. <i>Medicine (United States)</i> , 2022, 101, e31763.	0.4	4
586	Emergence of SARS-CoV-2 Omicron Variant and strategies for tackling the infection. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	9

#	ARTICLE	IF	CITATIONS
587	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
588	Antigenic escape is accelerated by the presence of immunocompromised hosts. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2022, 289, .	1.2	3
589	SARS-CoV-2 variants: Impact on biological and clinical outcome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
591	Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines. <i>Virologica Sinica</i> , 2022, 37, 783-785.	1.2	2
592	Predicting unseen antibodies' neutralizability via adaptive graph neural networks. <i>Nature Machine Intelligence</i> , 2022, 4, 964-976.	8.3	8
593	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients. <i>Vaccines</i> , 2022, 10, 1904.	2.1	6
594	A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
595	Rapid and Accurate On-Site Immunodiagnosics of Highly Contagious Severe Acute Respiratory Syndrome Coronavirus 2 Using Portable Surface-Enhanced Raman Scattering-Lateral Flow Assay Reader. <i>ACS Sensors</i> , 2022, 7, 3470-3480.	4.0	24
596	Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100850.	3.3	32
597	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	2
598	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
600	Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection. <i>Medical Microbiology and Immunology</i> , 2023, 212, 25-34.	2.6	4
601	The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13502.	1.8	6
602	Structural basis for the broad and potent cross-reactivity of an N501Y-centric antibody against sarbecoviruses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
603	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
604	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. <i>Nature</i> , 2023, 613, 558-564.	13.7	159
605	Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant. <i>Npj Vaccines</i> , 2022, 7, .	2.9	10
606	Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. <i>ELife</i> , 0, 11, .	2.8	53

#	ARTICLE	IF	CITATIONS
607	Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix. <i>Virologica Sinica</i> , 2022, 37, 860-873.	1.2	1
608	Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
609	Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
610	Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. <i>Nature Communications</i> , 2022, 13, .	5.8	26
611	Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	4
612	Ad26.COVS priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	1.9	4
613	Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster. <i>Antiviral Research</i> , 2023, 209, 105507.	1.9	3
614	Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130288.	1.1	4
615	Modelling SARS-CoV-2 spike-protein mutation effects on ACE2 binding. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 119, 108379.	1.3	4
616	COVID-19 Vaccination in Korea: Past, Present, and the Way Forward. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	20
617	Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1997.	2.1	4
618	Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy. <i>American Journal of Infection Control</i> , 2022, , .	1.1	1
620	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. <i>Science China Life Sciences</i> , 2023, 66, 658-678.	2.3	3
621	Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. <i>International Immunology</i> , 2023, 35, 197-207.	1.8	4
623	Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice. <i>Communications Medicine</i> , 2022, 2, .	1.9	4
624	Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11
625	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. <i>Cell Host and Microbe</i> , 2023, 31, 9-17.e3.	5.1	163
626	Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. <i>Molecular Immunology</i> , 2023, 156, 10-19.	1.0	3

#	ARTICLE	IF	CITATIONS
627	Safety of anti- SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study. <i>Thoracic Cancer</i> , 0, .	0.8	3
628	Omicron variant: assessing the duration of viral shedding and its implications. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	0
629	Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	13
631	Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models. <i>Voprosy Virusologii</i> , 2022, 67, 439-449.	0.1	0
632	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
634	Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	3
635	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. <i>Vaccines</i> , 2023, 11, 30.	2.1	3
638	Social Network Analysis of COVID-19 Research and the Changing International Collaboration Structure. <i>Journal of Shanghai Jiaotong University (Science)</i> , 2024, 29, 150-160.	0.5	1
639	The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. <i>IScience</i> , 2022, 25, 105720.	1.9	27
640	Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 1684-1692.	0.7	3
641	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
642	Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. <i>Cell</i> , 2023, 186, 279-286.e8.	13.5	455
643	Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
645	Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 85-97.	4.0	8
646	Bayesian Molecular Dating Analyses Combined with Mutational Profiling Suggest an Independent Origin and Evolution of SARS-CoV-2 Omicron BA.1 and BA.2 Sub-Lineages. <i>Viruses</i> , 2022, 14, 2764.	1.5	2
647	Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers. <i>Heliyon</i> , 2022, 8, e12125.	1.4	3
648	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
650	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. <i>Cell Reports</i> , 2022, 41, 111845.	2.9	46

#	ARTICLE	IF	CITATIONS
651	Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15264.	1.8	13
652	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. <i>Microbes and Infection</i> , 2023, 25, 105082.	1.0	5
653	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
654	A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
657	SARS-CoV-2â€™NÄ°N SÄœREGELEN EVRÄ°MÄ°: PANDEMÄ°NÄ°N SONUNA NE KADAR YAKINIZ?. <i>Journal of Biotechnology and Strategic Health Research</i> , 0, , .	0.8	0
658	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
659	Origin and Reversion of Omicron Core Mutations in the Evolution of SARS-CoV-2 Genomes. <i>Viruses</i> , 2023, 15, 30.	1.5	3
660	A comparative analysis exposes an amplification delay distinctive to SARS-CoV-2 Omicron variants of clinical and public health relevance. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
661	Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	2
662	Development, testing and validation of a SARS-CoV-2 multiplex panel for detection of the five major variants of concern on a portable PCR platform. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
665	Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients. <i>American Journal of Transplantation</i> , 2023, 23, 278-283.	2.6	2
667	Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. <i>MBio</i> , 2023, 14, .	1.8	14
668	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
670	Characterization of crossâ€reactive monoclonal antibodies against SARSâ€CoVâ€1 and SARSâ€CoVâ€2: Implication for rational design and development of panâ€sarbecovirus vaccines and neutralizing antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
671	Functionalized Fullerene for Inhibition of SARSâ€CoVâ€2 Variants. <i>Small</i> , 2023, 19, .	5.2	8
672	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	13.7	52
673	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
674	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11

#	ARTICLE	IF	CITATIONS
675	Affinity Exploration of SARS-CoV-2 RBD Variants to mAb-Functionalized Plasmonic Metasurfaces for Label-Free Immunoassay Boosting. <i>ACS Nano</i> , 2023, 17, 3383-3393.	7.3	12
677	RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq. <i>Cell Chemical Biology</i> , 2023, 30, 85-96.e6.	2.5	3
679	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. <i>Journal of Virology</i> , 0, , .	1.5	2
681	Humoral immunity for durable control of SARS-CoV-2 and its variants. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	6
682	Molecular fate-mapping of serum antibody responses to repeat immunization. <i>Nature</i> , 2023, 615, 482-489.	13.7	54
683	The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. <i>Cell Reports Medicine</i> , 2023, 4, 100893.	3.3	16
684	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1
685	Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 166-175.	1.5	6
686	On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. <i>Viruses</i> , 2023, 15, 70.	1.5	2
687	SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals. <i>Viruses</i> , 2023, 15, 101.	1.5	5
688	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	19
690	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
691	RNA Interference Approach Is a Good Strategy against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 100.	1.5	2
692	Emerging Dominant SARS-CoV-2 Variants. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 335-342.	2.5	12
693	Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. <i>Cell Reports Medicine</i> , 2023, 4, 100943.	3.3	31
694	Altered host protease determinants for SARS-CoV-2 Omicron. <i>Science Advances</i> , 2023, 9, .	4.7	12
695	Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. <i>Viruses</i> , 2023, 15, 321.	1.5	0
696	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. <i>PLoS Pathogens</i> , 2023, 19, e1011085.	2.1	5

#	ARTICLE	IF	CITATIONS
697	Voluntary risk mitigation behaviour can reduce impact of SARS-CoV-2: a real-time modelling study of the January 2022 Omicron wave in England. <i>BMC Medicine</i> , 2023, 21, .	2.3	1
698	SARS-CoV-2 and its impact on the cardiovascular and digestive systems â€” The interplay between new virus variants and human cells. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1022-1029.	1.9	2
699	Immunological and metabolic characteristics of the Omicron variants infection. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	2
700	Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study. <i>Transplantation</i> , 2023, 107, 1124-1135.	0.5	5
701	Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2023, 19, e1010822.	1.5	4
702	Viral immunity: Basic mechanisms and therapeutic applicationsâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1521, 32-45.	1.8	0
704	T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
705	PCIF1-mediated deposition of 5â€²-cap <i>N</i> ⁶ ,2â€²-O ² -dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	8
706	CaIn ₂ S ₄ â€”In ₂ O ₃ hybrid nanofibers with expedited photocarrier separation for fast photocatalytic bacterial inactivation under visible light. <i>Inorganic Chemistry Frontiers</i> , 0, , .	3.0	1
707	Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. <i>Vaccines</i> , 2023, 11, 318.	2.1	4
709	Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
710	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	4
711	SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	9
712	Single-epitope T cellâ€”based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. <i>JCI Insight</i> , 2023, 8, .	2.3	2
713	Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection. <i>Life Science Alliance</i> , 2023, 6, e202301969.	1.3	2
714	SARS-CoV-2 omicron variants are susceptible in vitro to <i>Artemisia annua</i> hot water extracts. <i>Journal of Ethnopharmacology</i> , 2023, 308, 116291.	2.0	8
715	Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2023, 660, 43-49.	1.0	2
716	An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics. <i>New Biotechnology</i> , 2023, 76, 13-22.	2.4	4

#	ARTICLE	IF	CITATIONS
717	Modeling the competitive transmission of the Omicron strain and Delta strain of COVID-19. <i>Journal of Mathematical Analysis and Applications</i> , 2023, 526, 127283.	0.5	9
718	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
719	The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on stability of the RBD-ACE2 complex. <i>Future Virology</i> , 2023, 18, 225-242.	0.9	3
720	Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2023, 176, 658-666.	2.0	10
721	A systematic study on the binding affinity of SARS-CoV-2 spike protein to antibodies. <i>AIMS Microbiology</i> , 2022, 8, 595-611.	1.0	2
722	Role of vaccine in fighting the variants of COVID-19. <i>Chaos, Solitons and Fractals</i> , 2023, 168, 113159.	2.5	2
723	Omicron mutations increase interdomain interactions and reduce epitope exposure in the SARS-CoV-2 spike. <i>IScience</i> , 2023, 26, 105981.	1.9	4
724	mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
725	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
726	Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model. <i>IScience</i> , 2023, 26, 106092.	1.9	5
727	Augmenting Vaccine Efficacy against Delta Variant with <i>Mycobacterium-w</i> TM -Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways. <i>Vaccines</i> , 2023, 11, 328.	2.1	0
729	High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. <i>PLoS Pathogens</i> , 2023, 19, e1011119.	2.1	2
730	Severity of SARS-CoV-2 Omicron variant infection in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2023, 42, 558-561.	0.3	4
731	Temporal Series Analysis of Population Cycle Threshold Counts as a Predictor of Surge in Cases and Hospitalizations during the SARS-CoV-2 Pandemic. <i>Viruses</i> , 2023, 15, 421.	1.5	1
733	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. <i>Pathogens</i> , 2023, 12, 244.	1.2	8
734	Convalescent Plasma Therapy against COVID-19: An update on the changing facets of the ongoing Pandemic. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	1
735	A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. <i>Vaccines</i> , 2023, 11, 371.	2.1	3
736	Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARS-CoV-2. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	0

#	ARTICLE	IF	CITATIONS
737	Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
738	Targeted photodynamic neutralization of SARS-CoV-2 mediated by singlet oxygen. <i>Photochemical and Photobiological Sciences</i> , 2023, 22, 1323-1340.	1.6	2
739	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
741	Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV. <i>Aids</i> , 2023, 37, 877-882.	1.0	3
742	A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. <i>Cell</i> , 2023, 186, 1263-1278.e20.	13.5	54
743	Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1966-1977.	1.9	16
744	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
746	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
747	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1
748	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
749	Searching for common ground. <i>Science</i> , 2023, 379, 655-655.	6.0	0
750	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
751	Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. <i>Structure</i> , 2023, 31, 253-264.e6.	1.6	3
752	Trapping virus-loaded aerosols using granular material composed of protein nanofibrils and iron oxyhydroxides nanoparticles. , 0, 3, .		0
754	Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
755	Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3638-3658.	5.7	2
756	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
758	Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4

#	ARTICLE	IF	CITATIONS
759	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
760	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. <i>Nature Methods</i> , 2023, 20, 512-522.	9.0	111
761	Development of broadly reactive antibody therapeutics for SARS-CoV-2. <i>Drug Delivery System</i> , 2022, 37, 388-394.	0.0	0
762	Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies. <i>IScience</i> , 2023, 26, 106283.	1.9	5
763	COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses. <i>EBioMedicine</i> , 2023, 89, 104485.	2.7	4
764	Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	23
766	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. <i>Antiviral Research</i> , 2023, 212, 105556.	1.9	2
767	Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. <i>Cytokine and Growth Factor Reviews</i> , 2023, 70, 13-25.	3.2	17
768	Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. <i>Viruses</i> , 2023, 15, 687.	1.5	4
770	Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost. <i>IScience</i> , 2023, 26, 106345.	1.9	3
772	A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	0
773	The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era. <i>American Journal of Medicine</i> , 2023, 136, 577-584.	0.6	4
774	Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. <i>Nature Immunology</i> , 2023, 24, 690-699.	7.0	16
775	The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?. <i>International Journal of Surgery</i> , 2023, 109, 1041-1043.	1.1	8
776	Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
777	Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	5
778	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
779	Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. <i>ELife</i> , 0, 12, .	2.8	16

#	ARTICLE	IF	CITATIONS
780	Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. <i>Journal of Clinical Medicine</i> , 2023, 12, 2371.	1.0	2
783	Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
784	Health Financing Challenges Towards Accomplishment of Sustainable Development Goals. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , 2023, , 63-83.	0.2	1
785	COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray. <i>Analytical Chemistry</i> , 2023, 95, 5610-5617.	3.2	4
786	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. <i>Nature Communications</i> , 2023, 14, .	5.8	6
787	Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. <i>ELife</i> , 0, 12, .	2.8	9
788	Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. <i>PLoS Pathogens</i> , 2023, 19, e1011231.	2.1	2
790	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
791	Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2023, 77, 229-236.	2.9	5
792	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. <i>Vaccine</i> , 2023, 41, 3003-3010.	1.7	1
793	Prediction of the SARS-CoV-2 Derived T-Cell Epitopes™ Response Against COVID Variants. <i>Computers, Materials and Continua</i> , 2023, 75, 3517-3535.	1.5	0
794	Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6642.	1.8	2
795	Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	2
796	Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. <i>Cell Discovery</i> , 2023, 9, .	3.1	2
797	Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination. <i>Microorganisms</i> , 2023, 11, 940.	1.6	1
798	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
799	Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. <i>Communications Biology</i> , 2023, 6, .	2.0	3
801	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0

#	ARTICLE	IF	CITATIONS
802	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
803	An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. <i>Nature Communications</i> , 2023, 14, .	5.8	11
805	Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. <i>International Journal of Infectious Diseases</i> , 2023, 132, 72-79.	1.5	4
806	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	5.8	12
807	SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor. <i>Acta Pharmaceutica Sinica B</i> , 2023, , .	5.7	1
808	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. <i>Heliyon</i> , 2023, 9, e15587.	1.4	1
809	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. <i>Zoonoses</i> , 2023, 3, .	0.5	1
810	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
812	NGS implementation for monitoring SARS-CoV-2 variants in Chicagoland: An institutional perspective, successes and challenges. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	1
819	Omicron variant evolution on vaccines and monoclonal antibodies. <i>Inflammopharmacology</i> , 2023, 31, 1779-1788.	1.9	9
826	Superspreading and Heterogeneity in Epidemics. , 2023, , 473-507.		0
920	Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	2
930	Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1). <i>Journal of Computer-Aided Molecular Design</i> , 0, , .	1.3	0
966	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
991	B cell responses to SARS-CoV-2. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , .	0.9	0
998	Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.		0
1011	A human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron. , 2024, 2, .		0